Life Technologies Introduces Custom-Tailored Genomic Analysis Tools for RNA Expression and Copy Number Variation Studies
by Mauricio Minotta - 11/29/10
CARLSBAD, Calif. – Nov. 29, 2010 – Life Technologies Corporation, a provider of innovative life science solutions, today announced the introduction of its Custom Plus TaqMan® Assays for RNA and Copy Number Variation (CNV) studies, each of which provides rigorous bioinformatics analysis on genomic regions of interest to complement its pre-designed assay product lines.
Copy number variation assays provide pharmaceutical, clinical and academic researchers with a powerful tool to detect and quantify CNVs -- changes in the number of genes or genomic sequences that are believed to play a role in drug metabolism and diseases such as neurological and immunological disorders as well as cancer.
Serving as highly reliable secondary platforms for validation studies following whole-genome scans, the new Custom Plus TaqMan® Copy Number Assays enable scientists to select pre-masked mouse or human genomic target sequences with additional bioinformatic analysis that includes genome specificity and reference assay compatibility checks to ensure the best possible assay design and robust performance.
The TaqMan® Custom Plus RNA Assays feature the same specificity and rigorous quality checks for scientists who study the gene expression of coding and non-coding RNA. Non-coding RNAs, molecules that are transcribed from the genome but are not translated into proteins, have been implicated in a broad range of cellular functions and diseases. Understanding the role they play in disease can point to targets for future diagnosis and therapy development.
“Highly reliable data is paramount for scientists who are conducting research with the potential to lead to a better understanding of health and disease,” said Sam Raha, Vice President and General Manager of Genomic Assays for Life Technologies. “The stringent analysis and quality control checks offered with the new TaqMan® Custom Plus assays are held to the same high standards of unrivaled accuracy and sensitivity that our portfolio of genomic assays is known for in laboratories around the world.”
In related news, Life Technologies is also announcing the expansion of its TaqMan® portfolio with a new set of more than 180,000 pre-designed mouse Copy Number Assays, including assays to common vector marker and reporter genes, which serve as screening tools to characterize transgenic mice for studies in genetic disorders, embryonic development and drug therapy testing.
TaqMan assays are For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.
About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact Mauricio Minotta